UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis
USA - NASDAQ:UTHR - US91307C1027 - Common Stock
474.72 USD
-1.82 (-0.38%)
474.72 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to UTHR. UTHR was compared to 533 industry peers in the Biotechnology industry. UTHR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. UTHR is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make UTHR a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
In the past year UTHR was profitable.
UTHR had a positive operating cash flow in the past year.
In the past 5 years UTHR has always been profitable.
UTHR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
UTHR has a Return On Assets of 17.30%. This is amongst the best in the industry. UTHR outperforms 96.06% of its industry peers.
Looking at the Return On Equity, with a value of 19.30%, UTHR belongs to the top of the industry, outperforming 95.50% of the companies in the same industry.
The Return On Invested Capital of UTHR (17.33%) is better than 96.81% of its industry peers.
UTHR had an Average Return On Invested Capital over the past 3 years of 14.96%. This is below the industry average of 19.19%.
The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(17.33%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
The Profit Margin of UTHR (40.65%) is better than 97.37% of its industry peers.
UTHR's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 48.65%, UTHR belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
In the last couple of years the Operating Margin of UTHR has grown nicely.
UTHR's Gross Margin of 88.59% is amongst the best of the industry. UTHR outperforms 90.06% of its industry peers.
In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so UTHR is creating value.
Compared to 1 year ago, UTHR has less shares outstanding
The number of shares outstanding for UTHR has been increased compared to 5 years ago.
Compared to 1 year ago, UTHR has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 20.15 indicates that UTHR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 20.15, UTHR belongs to the best of the industry, outperforming 90.06% of the companies in the same industry.
UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.15 |
ROIC/WACC1.99
WACC8.71%
2.3 Liquidity
A Current Ratio of 6.40 indicates that UTHR has no problem at all paying its short term obligations.
The Current ratio of UTHR (6.40) is better than 66.60% of its industry peers.
A Quick Ratio of 6.07 indicates that UTHR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.07, UTHR is in the better half of the industry, outperforming 65.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.90% over the past year.
The Earnings Per Share has been growing by 16.88% on average over the past years. This is quite good.
Looking at the last year, UTHR shows a quite strong growth in Revenue. The Revenue has grown by 13.50% in the last year.
Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 14.71% on average per year.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.57% on average per year.
The Revenue is expected to grow by 11.21% on average over the next years. This is quite good.
EPS Next Y14.15%
EPS Next 2Y9.73%
EPS Next 3Y7.6%
EPS Next 5Y11.57%
Revenue Next Year11.56%
Revenue Next 2Y8.55%
Revenue Next 3Y8.2%
Revenue Next 5Y11.21%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 17.99, UTHR is valued on the expensive side.
UTHR's Price/Earnings ratio is rather cheap when compared to the industry. UTHR is cheaper than 94.37% of the companies in the same industry.
UTHR is valuated rather cheaply when we compare the Price/Earnings ratio to 25.07, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 16.03, UTHR is valued correctly.
UTHR's Price/Forward Earnings ratio is rather cheap when compared to the industry. UTHR is cheaper than 94.37% of the companies in the same industry.
UTHR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.08.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.99 | ||
| Fwd PE | 16.03 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 96.06% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, UTHR is valued cheaply inside the industry as 95.12% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.23 | ||
| EV/EBITDA | 10.82 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.27
PEG (5Y)1.07
EPS Next 2Y9.73%
EPS Next 3Y7.6%
5. Dividend
5.1 Amount
UTHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
474.72
-1.82 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.47%
Inst Owner Change-5.48%
Ins Owners1.76%
Ins Owner Change3.75%
Market Cap21.47B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.91
Price Target499.6 (5.24%)
Short Float %3.79%
Short Ratio2.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)2%
PT rev (3m)30.11%
EPS NQ rev (1m)5.19%
EPS NQ rev (3m)6.6%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-1.74%
Revenue NQ rev (1m)1.36%
Revenue NQ rev (3m)1.47%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.99 | ||
| Fwd PE | 16.03 | ||
| P/S | 6.86 | ||
| P/FCF | 19.23 | ||
| P/OCF | 13.8 | ||
| P/B | 3.26 | ||
| P/tB | 3.32 | ||
| EV/EBITDA | 10.82 |
EPS(TTM)26.39
EY5.56%
EPS(NY)29.62
Fwd EY6.24%
FCF(TTM)24.68
FCFY5.2%
OCF(TTM)34.41
OCFY7.25%
SpS69.17
BVpS145.7
TBVpS143.12
PEG (NY)1.27
PEG (5Y)1.07
Graham Number294.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 20.15 |
F-Score8
WACC8.71%
ROIC/WACC1.99
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y14.15%
EPS Next 2Y9.73%
EPS Next 3Y7.6%
EPS Next 5Y11.57%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.56%
Revenue Next 2Y8.55%
Revenue Next 3Y8.2%
Revenue Next 5Y11.21%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year18.1%
EBIT Next 3Y5.05%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
Can you provide the valuation status for UNITED THERAPEUTICS CORP?
ChartMill assigns a valuation rating of 7 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Undervalued.
What is the profitability of UTHR stock?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for UTHR stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 17.99 and the Price/Book (PB) ratio is 3.26.
What is the financial health of UNITED THERAPEUTICS CORP (UTHR) stock?
The financial health rating of UNITED THERAPEUTICS CORP (UTHR) is 9 / 10.